DANVERS, Mass., March 21 /PRNewswire-FirstCall/ -- Medwave, Inc. , the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today the addition of its new Primo(TM) spot blood pressure monitoring product to its existing purchasing agreement with Amerinet, Inc., one of the nation’s leading healthcare group purchasing organizations. Medwave has been providing Amerinet members with blood pressure monitoring solutions since April 2001. Now, with the addition of Primo, Amerinet members have access to a very sophisticated and advanced method of blood pressure measurement for a multitude of clinical environments where clinicians face challenges with conventional blood pressure technology applications.
Primo is a handheld, sensor-based, spot blood pressure monitoring device that is placed on the wrist. Primo comfortably, easily, and accurately delivers a BP reading and pulse rate within seconds. Additionally, Primo requires no calibration for the life of the product, and the only maintenance required for Primo is battery replacement, which amounts to very little additional cost of ownership.
Tim O’Malley, President and CEO of Medwave, Inc., stated, “The employees at Medwave have worked tirelessly the past several years to position our technology as a logical alternative to traditional blood pressure cuff based products. Part of our strategy has been to enter into agreements with some of the large group purchasing organizations, such as Amerinet. When new products embedded with our core technology become available, we would then attempt to leverage those products into the existing agreements. Primo is an excellent example of the execution of that strategy. Primo’s advanced method of obtaining a point of care blood pressure value offers speed, accuracy and convenience that is simply not available in cuff based systems, and Primo is priced to be disruptive from an initial investment and cost of ownership perspective. We are very excited to provide Amerinet members access to this efficient and economical tool for their blood pressure monitoring needs.”
Medwave, Inc. develops, manufactures, and distributes sensor-based non- invasive blood pressure solutions. The company’s suite of products are designed for use in hospitals, clinics, doctor’s offices and almost anywhere else blood pressure monitoring takes place. Medwave has the required technology clearances to market its technology in the United States, Europe, and Asia, and Medwave’s technology is installed in over 500 hospitals and clinics worldwide. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered “forward-looking statements” and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in Medwave’s filings with the SEC, have affected and, in the future, could affect Medwave’s actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave’s products, Medwave’s success in creating effective distribution channels for its products, Medwave’s ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward- looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), and Primo(TM) are trademarks of Medwave, Inc.
Medwave, Inc.
CONTACT: Investor Relations, Jodie Chastain, +1-800-894-7601, or MediaRelations, Kevin Sawyer, +1-612-465-8356, both of Medwave, Inc.
Web site: http://www.medwave.com/
